China’s VivaVision Biotech Inc. has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase II clinical trial for its in-house developed drug candidate, VVN461. The trial will assess the efficacy of VVN461 as a treatment for inflammation following cataract surgery.
VVN461’s Potency and Safety Profile
VVN461 is a potent small-molecule immunomodulator with high inhibitory activity across multiple cytokine pathways, effectively reducing and alleviating inflammatory reactions in the eye. Human pharmacokinetic studies have demonstrated that VVN461 eye drops have low exposure to plasma, suggesting a strong anti-inflammatory efficacy with reduced systemic toxicity, which points to a robust safety profile.- Flcube.com
